Active, Not Recruiting
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma - CC-99712-MM-001
Updated: 29 January, 2024 | ClinicalTrials.gov
Phase
Gender(s)
Age Range
Active, Not Recruiting
Participants must satisfy the following criteria to be enrolled in the study: Inclusion - Participant is ≥ 18 years of age at the time of signing the ICF. - Participant has a history of multiple myeloma (MM) with relapsed and/or refractory disease - Participant must have measurable disease. - Participant has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. Exclusion Criteria - Participant has symptomatic central nervous system involvement of MM. - Participant had a prior autologous stem cell transplant ≤ 3 months prior to starting CC-99712. - Participant had a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-99712 or is on systemic immunosuppression for graft-versus host disease. - Subject is a pregnant or lactating female. - Subject has known human immunodeficiency virus (HIV) infection. - Subject has active hepatitis B or C (HBV/HCV) infection. Other protocol-defined inclusion/exclusion criteria apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
MLTNO2000046
